Agmatine Improves Cognitive Dysfunction and Prevents Cell Death in a Streptozotocin-Induced Alzheimer Rat Model

키워드

참고문헌 (89)

1. Hyman BT, "Alzheimer’s disease", Annu Rev Public Health, 10, pp.115~140 (1989)
2. Van Hoesen GW, "The parahippocampal gyrus in Alzheimer’s disease. Clinical and preclinical neuroanatomical correlates", Ann N Y Acad Sci, 911, pp.254~274 (2000)
3. Arispe N, "Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum", Proc Natl Acad Sci U S A, 90, pp.567~571 (1993)
4. Furukawa K, "Amyloid beta protein-induced irreversible current in rat cortical neurones", Neuroreport, 5, pp.2016~2018 (1994)
5. Mattson MP, "beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer’s disease", Trends Neurosci, 16, pp.409~414 (1993)
6. Alberdi E, "Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors", Cell Calcium, 47, pp.264~272 (2010)
7. Kelly BL, "beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons", J Biol Chem, 281, pp.28079~28089 (2006)
8. Lester-Coll N, "Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease", J Alzheimers Dis, 9, pp.13~33 (2006)
9. Butterfield DA, "Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain", Brain Res, 1000, pp.1~7 (2004)
10. Lannert H, "Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats", Behav Neurosci, 112, pp.1199~1208 (1998)
11. Gibson GE, "Oxidative stress in Alzheimer’s disease", Neurobiol Aging, 26, pp.575~578 (2005)
12. Grünblatt E, "Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein", J Neurochem, 101, pp.757~770 (2007)
13. Weinstock M, "Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity", J Neural Transm, 111, pp.347~366 (2004)
14. Dröge W, "Aberrant insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging", Antioxid Redox Signal, 10, pp.661~678 (2008)
15. Hoyer S, "Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative", energy brain metabolism and in behavior in adult rats, 1999, pp.893, 301~303
16. Hoyer S, "Glucose metabolism and insulin receptor signal transduction in Alzheimer disease", Eur J Pharmacol, 490, pp.115~125 (2004)
17. Ahmad M, "Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences", J Neurochem, 93, pp.94~104 (2005)
18. Ansari MA, "Selenium protects cerebral ischemia in rat brain mitochondria", Biol Trace Elem Res, 101, pp.73~86 (2004)
19. Arteni NS, "Agmatine facilitates memory of an inhibitory avoidance task in adult rats", Neurobiol Learn Mem, 78, pp.465~469 (2002)
20. Liu P, "Behavioral effects of agmatine in naive rats are task- and delay-dependent", Neuroscience, 163, pp.82~96 (2009)
21. Lu W, "Agmatine inhibits morphine-induced memory impairment in the mouse step-down inhibitory avoidance task", Pharmacol Biochem Behav, 97, pp.256~261 (2010)
22. McKay BE, "Learning and memory in agmatine-treated rats", Pharmacol Biochem Behav, 72, pp.551~557 (2002)
23. Zarifkar A, "Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis", Eur J Pharmacol, 634, pp.84~88 (2010)
24. Feng Y, "Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats", Pediatr Res, 52, pp.606~611 (2002)
25. Kim JH, "Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury", EXPERIMENTAL NEUROLOGY, 189(1), pp.122~130 (2004)
26. Regunathan S, "Agmatine levels in the cerebrospinal fluid of normal human volunteers", J Pain Palliat Care Pharmacother, 23, pp.35~39 (2009)
27. Reis DJ, "Agmatine: a novel neurotransmitter?", Adv Pharmacol, 42, pp.645~649 (1998)
28. Regunathan S, "Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation", J Pharmacol Exp Ther, 276, pp.1272~1282 (1996)
29. Halaris A, "Agmatine: metabolic pathway and spectrum of activity in brain", CNS Drugs, 21, pp.885~900 (2007)
30. Reis DJ, "Is agmatine a novel neurotransmitter in brain?", Trends Pharmacol Sci, 21, pp.187~193 (2000)
31. Alam J, "Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene", J Biol Chem, 274, pp.26071~26078 (1999)
32. Motohashi H, "Nrf2-Keap1 defines a physiologically important stress response mechanism", Trends Mol Med, 10, pp.549~557 (2004)
33. Ramprasath T, "Potential impact of genetic variants in Nrf2 regulated antioxidant genes and risk prediction of diabetes and associated cardiac complications", Curr Med Chem, 20, pp.4680~4693 (2013)
34. Wild AC, "Overlapping antioxidant response element and PMA response element sequences mediate basal and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase catalytic subunit gene", Biochem J, 332(Pt 2), pp.373~381 (1998)
35. Tomobe K, "Age-related changes of Nrf2 and phosphorylated GSK-3β in a mouse model of accelerated aging (SAMP8)", Arch Gerontol Geriatr, 54, pp.e1~e7 (2012)
36. Venugopal R, "Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene", Proc Natl Acad Sci U S A, 93, pp.14960~14965 (1996)
37. Kanninen K, "Targeting Glycogen Synthase Kinase-3β for Therapeutic Benefit against Oxidative Stress in Alzheimer’s Disease: Involvement of the Nrf2-ARE Pathway", Int J Alzheimers Dis, 2011, pp.985085~ (2011)
38. Li XH, "Allicin ameliorates cardiac hypertrophy and fibrosis through enhancing of Nrf2 antioxidant signaling pathways", Cardiovasc Drugs Ther, 26, pp.457~465 (2012)
39. Yang Y, "Change of Nrf2 expression in rat hippocampus in a model of chronic cerebral hypoperfusion", Int J Neurosci (2013)
40. Rodrigues L, "Treadmill training restores spatial cognitive deficits and neurochemical alterations in the hippocampus of rats submitted to an intracerebroventricular administration of streptozotocin", J Neural Transm, 117, pp.1295~1305 (2010)
41. Morris R, "Developments of a water-maze procedure for studying spatial learning in the rat", J Neurosci Methods, 11, pp.47~60 (1984)
42. Paul CA, "Perfusion of brain tissues with fixative", CSH Protoc, 2008 (2008)
43. Flynn BL, "Pharmacologic management of Alzheimer disease, Part I: Hormonal and emerging investigational drug therapies", Ann Pharmacother, 33, pp.178~187 (1999)
44. Sharma M, "Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats", Life Sci, 71, pp.2489~2498 (2002)
45. Selkoe DJ, "Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein", J Alzheimers Dis, 3, pp.75~80 (2001)
46. Salkovic-Petrisic M, "Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach", J Neural Transm Suppl, pp.217~233 (2007)
47. Maftei M, "Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer’s disease patients", PLoS One, 8, pp.e68996~ (2013)
48. Selkoe DJ, "Alzheimer’s disease: a central role for amyloid", J Neuropathol Exp Neurol, 53, pp.438~447 (1994)
49. Varadarajan S, "Review: Alzheimer’s amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity", J Struct Biol, 130, pp.184~208 (2000)
50. Varadarajan S, "Different mechanisms of oxidative stress and neurotoxicity for Alzheimer’s A beta(1--42) and A beta(25--35)", J Am Chem Soc, 123, pp.5625~5631 (2001)
51. MK-801 at therapeutic concentrations in postmortem human frontal cortex, "Eur J Pharmacol", 1989, 589~590
52. Piletz JE, "Agmatine: clinical applications after 100 years in translation", Drug Discov Today, 18, pp.880~893 (2013)
53. Salloway S, "Disease-modifying therapies in Alzheimer’s disease", Alzheimers Dement, 4, pp.65~79 (2008)
54. Wang WP, "Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons", Brain Res, 1084, pp.210~216 (2006)
55. O’Neill C, "Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer’s disease", Biochem Soc Trans, 40, pp.721~727 (2012)
56. Freude S, "Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer’s disease", FASEB J, 23, pp.3315~3324 (2009)
57. Craft S, "Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose", Arch Gen Psychiatry, 56, pp.1135~1140 (1999)
58. Park CR, "Intracerebroventricular insulin enhances memory in a passive-avoidance task", Physiol Behav, 68, pp.509~514 (2000)
59. van der Heide LP, "Insulin signaling in the central nervous system: learning to survive", Prog Neurobiol, 79, pp.205~221 (2006)
60. Wang YT, "Regulation of NMDA receptors by tyrosine kinases and phosphatases", Nature, 369, pp.233~235 (1994)
61. van der Heide LP, "Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner", J Neurochem, 94, pp.1158~1166 (2005)
62. Zhao WQ, "Insulin and the insulin receptor in experimental models of learning and memory", Eur J Pharmacol, 490, pp.71~81 (2004)
63. Park CR, "Cognitive effects of insulin in the central nervous system", Neurosci Biobehav Rev, 25, pp.311~323 (2001)
64. Liu Y, "Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes", J Pathol, 225, pp.54~62 (2011)
65. Ahn SK, "Protective effects of agmatine on lipopolysaccharide-injured microglia and inducible nitric oxide synthase activity", LIFE SCIENCES, 91(25-26), pp.1345~1350 (2012), PERGAMON-ELSEVIER SCIENCE LTD
66. Bokara KK, "Retroviral expression of arginine decarboxylase attenuates oxidative burden in mouse cortical neural stem cells", Stem Cells Dev, 20, pp.527~537 (2011)
67. 서수경, "Overexpression of Human Arginine Decarboxylase Rescues Human Mesenchymal Stem Cells against H2O2 Toxicity through Cell Survival Protein Activation", Journal of Korean Medical Science, 28(3), pp.366~373 (2013), 대한의학회
68. Liu P, "Differential effects of i.c.v. microinfusion of agmatine on spatial working and reference memory in the rat", Neuroscience, 159, pp.951~961 (2009)
69. Frölich L, "Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment", Arzneimittelforschung, 45, pp.443~446 (1995)
70. Launer LJ, "Anti-oxidants and cognitive function: a review of clinical and epidemiologic studies", J Neural Transm Suppl, 53, pp.1~8 (1998)
71. Mikati MA, "Hippocampal programmed cell death after status epilepticus: evidence for NMDA-receptor and ceramide-mediated mechanisms", Epilepsia, 44, pp.282~291 (2003)
72. Brouillette J, "The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer’s Disease", Curr Pharm Des (2013)
73. Texidó L, "Amyloid β peptide oligomers directly activate NMDA receptors", Cell Calcium, 49, pp.184~190 (2011)
74. Feng Z, "Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism", Free Radic Biol Med, 37, pp.1790~1801 (2004)
75. Montiel T, "Role of oxidative stress on beta-amyloid neurotoxicity elicited during impairment of energy metabolism in the hippocampus: protection by antioxidants", Exp Neurol, 200, pp.496~508 (2006)
76. Pavlik VN, "Vitamin E use is associated with improved survival in an Alzheimer’s disease cohort", Dement Geriatr Cogn Disord, 28, pp.536~540 (2009)
77. Sano M, "A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study", N Engl J Med, 336, pp.1216~1222 (1997)
78. Ishrat T, "Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats", Behav Brain Res, 171, pp.9~16 (2006)
79. Pathan AR, "Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats", Life Sci, 79, pp.2209~2216 (2006)
80. Sharma M, "Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment", Life Sci, 68, pp.1021~1029 (2001)
81. Ferreiro E, "Bcl-2 overexpression protects against amyloid-beta and prion toxicity in GT1-7 neural cells", J Alzheimers Dis, 12, pp.223~228 (2007)
82. Rohn TT, "Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2", J Neurosci, 28, pp.3051~3059 (2008)
83. Kong J, "Effects of nicorandil in neuroprotective activation of PI3K", AKT pathways in a cellular model of Alzheimer’s disease, 2013, pp.70, 233~241
84. Kudo W, "Inhibition of Bax protects neuronal cells from oligomeric Aβ neurotoxicity", Cell Death Dis, 3, pp.e309~ (2012)
85. Lin MT, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases", Nature, 443, pp.787~795 (2006)
86. Slee EA, "Serial killers: ordering caspase activation events in apoptosis", Cell Death Differ, 6, pp.1067~1074 (1999)
87. Montagnani M, "Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179)", J Biol Chem, 276, pp.30392~30398 (2001)
88. Scheid MP, "PKB", AKT: functional insights from genetic models, 2001, pp.2, 760~768
89. Brunet A, "Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway", Curr Opin Neurobiol, 11, pp.297~305 (2001)

관련 논문AI추천